These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1124148)

  • 41. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
    Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
    Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future?
    Sönksen PH; Russell-Jones D; Jones RH
    Horm Res; 1993; 40(1-3):68-79. PubMed ID: 8300053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial.
    Scott IU; Jackson GR; Quillen DA; Larsen M; Klein R; Liao J; Holfort S; Munch IC; Gardner TW
    JAMA Ophthalmol; 2014 May; 132(5):535-43. PubMed ID: 24604308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
    Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
    Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of diabetic retinopathy.
    el-Massri A
    Bull Ophthalmol Soc Egypt; 1968; 61(65):23-30. PubMed ID: 4909179
    [No Abstract]   [Full Text] [Related]  

  • 46. [Results of laser photocoagulation in patients with diabetic retinopathy developed as a complication of diabetes type 2].
    Wilczyński M; Dzivgielewski K
    Klin Oczna; 2006; 108(1-3):66-9. PubMed ID: 16883944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two years' fluorescein follow-up of diabetic microaneurysms.
    Ferrer O
    Trans Ophthalmol Soc U K (1962); 1966; 86():497-506. PubMed ID: 5226592
    [No Abstract]   [Full Text] [Related]  

  • 49. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis.
    Hellman L; Yoshida K; Zumoff B; Levin J; Kream J; Fukushima DK
    J Clin Endocrinol Metab; 1976 May; 42(5):912-7. PubMed ID: 178684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No evidence for increased growth hormone responses to growth hormone-releasing hormone in patients with diabetic retinopathy.
    Pietschmann P; Schernthaner G; Prskavec F; Gisinger C; Freyler H
    Diabetes; 1987 Feb; 36(2):159-62. PubMed ID: 3100367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.
    Ophthalmology; 1991 May; 98(5 Suppl):786-806. PubMed ID: 2062513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two years fluorescein follow-up of diabetic microaneurysms.
    Ferrer O
    Ophthalmologica; 1967; 154(1):6-20. PubMed ID: 6059594
    [No Abstract]   [Full Text] [Related]  

  • 53. Growth hormone's role in diabetic microangiopathy.
    Lundbaek K
    Diabetes; 1976; 25(2 SUPPL):845-9. PubMed ID: 985606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion.
    Blankestijn PJ; Derkx FH; Birkenhäger JC; Lamberts SW; Mulder P; Verschoor L; Schalekamp MA; Weber RF
    J Clin Endocrinol Metab; 1993 Aug; 77(2):498-502. PubMed ID: 8345058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy.
    Boehm BO; Lang GK; Jehle PM; Feldman B; Lang GE
    Horm Metab Res; 2001 May; 33(5):300-6. PubMed ID: 11440277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retinal laser photocoagulation in diabetic patients causes prolactin, growth hormone and cortisol release.
    Pontiroli AE; Baio G; Maffi P; Menchini U; Brancato R; Pozza G
    J Endocrinol Invest; 1988 May; 11(5):389-91. PubMed ID: 3183302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fundus autofluorescence and colour fundus imaging compared during telemedicine screening in patients with diabetes.
    Kolomeyer AM; Baumrind BR; Szirth BC; Shahid K; Khouri AS
    J Telemed Telecare; 2013 Jun; 19(4):209-12. PubMed ID: 24163061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secretion of growth hormone in the insulin test, and the development of diabetic microangiopathy.
    Sieradzki J
    Pol Med Sci Hist Bull (1973); 1976; 15(2):191-6. PubMed ID: 959044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man.
    Wiedemann E; Schwartz E; Frantz AG
    J Clin Endocrinol Metab; 1976 May; 42(5):942-52. PubMed ID: 178687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Secretion of growth hormone in hyperthyroidism].
    Hervás F; Morreale de Escobar G; Escobar Del Rey F; Pozuelo V
    Rev Iber Endocrinol; 1976; 23(134):147-55. PubMed ID: 935730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.